Ceftriaxone exerts antitumor effects in MYCN ‐driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13553 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Pamorn Chittavanich und 8 weiteren Autor:innen. Beteiligte Einrichtung: Program in Translational Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Retinoblastoma, Neuroblastoma, Retinal Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health System Research Institute, Mahidol University, Thailand Research Fund (TRF) and Office of the Higher Education Commission (OHEC).
Abstract (Originalsprache)
MYCN proto‐oncogene, bHLH transcription factor ( MYCN ) amplification is associated with aggressive retinoblastoma (RB) and neuroblastoma (NB) cancer recurrence that is resistant to chemotherapies. Therefore, there is an urgent need to identify new therapeutic tools. This study aimed to evaluate the potential repurposing of ceftriaxone for the treatment of MYCN ‐amplified RB and NB, based on the clinical observations that the drug was serendipitously found to decrease the volume of the MYCN ‐driven RB subtype. Using patient‐derived tumor organoids and tumor cell lines, we demonstrated that ceftriaxone is a potent and selective growth inhibitor targeting MYCN ‐driven RB and NB cells. Profiling of drug‐induced transcriptomic changes, cell‐cycle progression, and apoptotic death indicated cell‐cycle arrest and death of drug‐treated MYCN ‐amplified tumor cells. Drug target identification, using an affinity‐based proteomic and molecular docking approach, and functional studies of the target proteins revealed that ceftriaxone targeted DEAD‐box helicase 3 X‐linked (DDX3X), thereby inhibiting translation in MYCN ‐amplified tumors but not in MYCN‐ nonamplified cells. The data suggest the feasibility of repurposing ceftriaxone as an anticancer drug and provide insights into the mechanism of drug action, highlighting DDX3X as a potential target for treating MYCN ‐driven tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program in Translational Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Functional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, Thailand.
- Department of Ophthalmology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
- Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Rossukon Kaewkhaw
Förderung
- Health System Research Institute
- Mahidol University
- Thailand Research Fund (TRF) and Office of the Higher Education Commission (OHEC)
Zitieren
APA
Chittavanich, P., Saengwimol, D., Roytrakul, S., Rojanaporn, D., Chaitankar, V., Srimongkol, A., Anurathapan, U., Hongeng, S., & Kaewkhaw, R. (2024). Ceftriaxone exerts antitumor effects in MYCN ‐driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression. Molecular Oncology. https://doi.org/10.1002/1878-0261.13553
Vancouver
Chittavanich P, Saengwimol D, Roytrakul S, Rojanaporn D, Chaitankar V, Srimongkol A, et al. Ceftriaxone exerts antitumor effects in MYCN ‐driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression. Molecular Oncology. 2024. doi:10.1002/1878-0261.13553
BibTeX
@article{Chittavanich2024,
author = {Chittavanich, Pamorn and Saengwimol, Duangporn and Roytrakul, Sittiruk and Rojanaporn, Duangnate and Chaitankar, Vijender and Srimongkol, Atthapol and Anurathapan, Usanarat and Hongeng, Suradej and Kaewkhaw, Rossukon},
title = {Ceftriaxone exerts antitumor effects in MYCN ‐driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13553}
}
EUVIMED